Tiziana Life Sciences – TR1 August 28, 2020 – Posted in: Tiziana Life Sciences (TILS)

28th August, 2020 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Tiziana Life Sciences PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the…

Tiziana Life Sciences – Amended ADS Registration Statement – Posted in: Tiziana Life Sciences (TILS)

28th August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement ADS Registration Statement filed in order to Increase Capacity under the ADS Facility to Exchange Ordinary Shares for ADSs Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced the clarification of…

(No title) August 27, 2020 – Posted in: Tiziana Life Sciences (TILS)

27th August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive Interview Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced that an interview with its CEO and CSO Dr. Kunwar Shailubhai is now available. In the interview,…

Tiziana Life Sciences – Grant of Options, Director Dealings August 26, 2020 – Posted in: Tiziana Life Sciences (TILS)

26th August, 2020 Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Grant of options – Director dealings Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the board of directors of the Company (the “Board” or “Directors”), with Mr Simon and Mr Brancaccio absenting themselves on grounds of interest, has awarded the following options on 25 August…

Tiziana Life Sciences – Patent Granted August 24, 2020 – Posted in: Tiziana Life Sciences (TILS)

24th August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for Covid-19 and other pulmonary diseases Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent…

Tiziana Life Sciences – Patent Granted on the use of Milciclib August 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

21st August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other Cancers Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent on use…

Tiziana Life Sciences – Patent Granted August 18, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease 18 August, 2020 Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent on use and methods of treatment…

Tiziana Life Sciences (TILS) – Closing of $57.25 Million Offering August 5, 2020 – Posted in: Minexia - NR Private Market, Tiziana Life Sciences (TILS)

5th August, 2020 Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering London, New York 5 August 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces the closing of its registered direct offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. As announced on 3 August 2020, Tiziana issued 11,009,615…

Tiziana Life Sciences (TILS) – Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients August 4, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tuesday 4th August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients · Recently signed agreements with four contract research organizations (“CROs”) to initiate GMP manufacturing, develop inhalation technology, conduct inhalation safety toxicity study in monkeys, and initiate a human clinical trial in COVID-19 patients This announcement contains inside information…

Tiziana Life Sciences (TILS)- Issue of Equity August 3, 2020 – Posted in: Tiziana Life Sciences (TILS)

Monday 3rd August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million New York and London, August 3, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced it has entered into definitive agreements with investors for the purchase and sale of 11,009,615 of the Company’s American Depositary Shares…

« First
Previous
1
2
3
4
5
...
11
Next
Last »